Nutriband Inc. (NTRB) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 30, 2026. Nutriband Inc. is a Nevada corporation focused on developing transdermal pharmaceutical products using its proprietary AVERSA abuse-deterrent technology. The company operates through two primary segments: Pocono Pharmaceuticals (contract manufacturing and sales of goods) and 4P Therapeutics (research and development of pharmaceutical products). The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $433,399 | $667,432 |
| Gross Profit | $196,801 | $251,981 |
| Gross Margin | 45.4% | 37.8% |
| Net Loss | $(1,241,956) | $(1,388,869) |
| Net Loss Per Share (Basic/Diluted) | $(0.10) | $(0.12) |
| Cash and Cash Equivalents | $4,006,184 | $2,964,099 |
| Working Capital | $3,544,125 | $4,204,437 |
| Net Cash Used in Operating Activities | $(563,104) | $(1,336,972) |
| Total Debt (Current + Long-Term) | $159,163 | Filing text does not provide a clear total for Q1 2025 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 35% year-over-year, driven by a loss of a principal customer in the Pocono Pharmaceuticals segment who moved operations to Asia. The 4P Therapeutics segment generated no revenue in either period.
- Improved Gross Margin: Despite lower revenue, gross margin improved from 37.8% to 45.4% due to a more favorable sales mix.
- Reduced Operating Loss: Net loss narrowed by approximately $147,000 compared to the prior year. This was primarily due to a significant reduction in Research and Development (R&D) expenses ($247,261 vs. $683,426) attributed to reduced labor costs.
- Increased SG&A: Selling, General, and Administrative expenses increased by roughly 22.6% to $1.2 million, driven by higher compensation-based expenses.
- Stock-Based Compensation: The company recorded a non-cash expense of $552,458 for warrants issued for services in Q1 2026, compared to $63,350 for shares issued for services in Q1 2025.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management believes the substantial doubt regarding the company's ability to continue as a going concern has been alleviated. With $4.0 million in cash and a $5.0 million credit line facility (currently undrawn), management projects sufficient funds to operate for the next 12 months.
- Product Development: The company is focused on the development of AVERSA Fentanyl in partnership with Kindeva Drug Delivery. As of April 30, 2026, $5.2 million has been incurred under this agreement, with a remaining budget of $3.4 million through NDA submission. A $3.0 million milestone payment is due upon FDA approval.
- Legal Proceedings: The company is a defendant in a lawsuit initiated by Joseph Gunnar, LLC and Lucosky Brookman LLP seeking over $500,000 in damages plus punitive fees regarding a terminated engagement letter. The company has filed counterclaims seeking $2.0 million. The case is currently in the discovery stage.
- Internal Controls: Management disclosed that disclosure controls and procedures are not effective due to material weaknesses, including a lack of segregation of duties and reliance on third-party consultants. Steps are being taken to hire qualified accounting personnel to address these issues.
- Risk Factors: Key risks include the inability to achieve profitability, dependence on FDA approval for lead products, potential dilution from future equity offerings, and macroeconomic uncertainties including geopolitical conflicts (e.g., war with Iran) affecting global markets.
Investor Verification Checklist
- Customer Concentration: Verify the impact of the lost principal customer in the Pocono segment and the sustainability of the remaining revenue base.
- Capital Sufficiency: Confirm the status of the $5.0 million credit line with TII Jet Services and the timeline for the next potential capital raise given the burn rate.
- Legal Exposure: Monitor the status of the Gunnar/LB lawsuit and the potential financial impact of the counterclaims or settlement.
- Internal Control Remediation: Assess the progress in hiring qualified accounting staff to resolve the material weaknesses in internal controls over financial reporting.
- R&D Milestones: Track the progress of the AVERSA Fentanyl clinical trials and the $3.4 million remaining budget with Kindeva.